Antithrombotic Drugs Market to Reach $77,584.2 Million in 2035, Growing at 3.1% CAGR

Antithrombotic drugs market valued at $57,603.1 million in 2025 and is projected to reach $77,584.2 million by 2035, growing at a CAGR of 3.1% during the forecast period (2026-2035). The market encompasses a broad range of pharmacological therapies designed to prevent and treat thrombotic disorders by inhibiting blood clot formation, including anticoagulants, antiplatelet agents, and thrombolytics. These therapies are widely used across acute and chronic cardiovascular conditions, supported by evolving clinical guidelines and increasing adoption of novel oral anticoagulants (NOACs). The market is witnessing steady growth driven by increasing awareness of thrombotic disorders, expanding screening and diagnostic capabilities, and strong clinical adoption of advanced anticoagulant therapies. Growth is further supported by continuous innovation in drug development, including factor Xa inhibitors and combination therapies aimed at improving efficacy and safety profiles. Additionally, expanding healthcare access in emerging economies and growing investments in cardiovascular disease management programs are reinforcing long-term market expansion.

Browse the full report description of “Antithrombotic Drugs Market Size, Share & Trends Analysis Report by Route of Administration (Oral and Parenteral), By Application (Deep Vein Thrombosis, Atrial Fibrillation, Pulmonary Embolism, and Others) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/anthithrombotic-drugs-market

According to the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), cardiovascular diseases account for approximately 17.9 million deaths annually worldwide, representing the leading cause of mortality and a key driver for antithrombotic drug demand. Furthermore, atrial fibrillation affects over 33 million people globally, significantly increasing the risk of stroke and systemic embolism, thereby supporting long-term therapeutic utilization.

Key Statistics: Antithrombotic Drugs at a Glance

• Cardiovascular diseases cause nearly 17.9 million deaths annually worldwide, driving demand for preventive and therapeutic antithrombotic drugs.
• Atrial fibrillation affects over 33 million individuals globally, representing a major indication for long-term anticoagulant therapy.
• Venous thromboembolism, including DVT and pulmonary embolism, impacts an estimated 10 million people each year globally, reinforcing sustained need for antithrombotic treatment.

Key Innovators Driving Antithrombotic Drugs Transformation

The key players in the antithrombotic drugs market include Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Johnson & Johnson Services, Inc., Pfizer Inc, among others.

• In May 2025, Bristol Myers Squibb advanced clinical research on anticoagulant therapies as part of its cardiovascular portfolio, focusing on treatment safety and outcomes in high-risk patient populations.
• In March 2025, Bayer AG invested in real-world evidence studies to support the use of its oral anticoagulant therapies in different healthcare markets.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Route of Administration
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Johnson & Johnson Services, Inc., Pfizer Inc, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Antithrombotic Drugs Market Report Segment

By Route of Administration

• Oral
• Parenteral

By Application

• Deep Vein Thrombosis
• Atrial Fibrillation
• Pulmonary Embolism
• Others

Global Antithrombotic Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/anthithrombotic-drugs-market